- Open Access
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road
Journal of Clinical Movement Disordersvolume 4, Article number: 2 (2017)
Disruption of the frontal lobes and its associated networks are a common consequence of neurodegenerative disorders. Given the wide range of cognitive, behavioral and motor processes in which the frontal lobes are involved, there can be a great variety of manifestations depending on the pathology distribution. The most common are the behavioral variant of frontotemporal dementia (bvFTD) and the frontal variant of Alzheimer’s disease (fvAD), which are particularly challenging to disentangle. Recognizing fvAD from bvFTD-related pathologies is a diagnostic challenge and a critical need in the management and counseling of these patients.
Here we present three pathology-proven cases of Alzheimer’s disease initially misdiagnosed as bvFTD and discuss the distinctive or less overlapping historical, examination, and laboratory findings of fvAD and bvFTD, deriving analogies for mnemonic endurance from the Wizard of Oz worldview.
The Yellow Brick Road to diagnosing these disorders may be served by the metaphor of fvAD as the irritable, paranoid, and tremulous Scarecrow and bvFTD the heartless, ritualistic, and rigid Tin Man. An Oz-inspired creative license may help the clinician recognize the differential disease progression, caregiver burden, and treatment response of fvAD compared with bvFTD.
While an amnestic syndrome is the most common presentation of Alzheimer’s disease (AD), atypical variants have been recognized. These include the posterior cortical atrophy syndrome, corticobasal syndrome, logopenic variant of primary progressive aphasia, and frontal variant (fvAD) [1, 2]. FvAD is an under-recognized form of AD, often misdiagnosed as more common frontal lobe syndromes such as the behavioral variant of frontotemporal dementia (bvFTD) or vascular dementia affecting frontal networks. We present three patients with pathology-proven AD presenting with cognitive and behavioral impairment in the context of parkinsonian features, initially diagnosed as bvFTD. We then discuss the features in the history, examination and ancillary testing that may have helped distinguishing these entities. Finally, we suggest analogies from Frank Baum’s novel “The Wonderful Wizard of Oz” to help the reader (without trivializing) remember the phenotypic differences between them.
A 72-year-old man had progressive decline in gait and cognition following a fall 10 months earlier. He was forgetful and his gait shuffling and unstable. In the following months, his family noted a change in personality with apathy and lack of concern for his appearance. His family history was significant for AD in his mother and Parkinson disease (PD) in two paternal cousins. On exam, he was hypophonic and hypomimic. He exhibited symmetric rigidity and bradykinesia and hand myoclonus on outstretched arms. His gait was slow and short-stepped, with stooped posture, reduced arm swing, gait freezing on turns, and inability to tandem walk (Additional file 1: Video S1). Postural reflexes were impaired. Unified Parkinson’s Disease Rating Scale (UPDRS) motor score was 23.5 on initial examination. In addition, he demonstrated bilateral ideomotor apraxia to transitive gestures. Montreal cognitive assessment (MoCA) score was 21/30 with deficits in executive function, phonemic fluency, and attention. Frontal assessment battery (FAB) was 15/18. His brain MRI revealed atrophy in the frontal, temporal, and parietal regions, somewhat worse in the right hemisphere, with increased signal in the periventricular white matter and right frontal lobe (Fig. 1a, d). Patient and family declined amyloid-imaging and cerebral spine fluid (CSF) biomarkers. A diagnosis of possible bvFTD with parkinsonism was made based on apathy, poor personal hygiene, and predominantly executive dysfunction on cognitive testing. Levodopa was titrated to a dose of 1600 mg/day with mild improvement in gait speed but also with development of mild truncal dyskinesia. Clonazepam 0.5 mg daily and venlafaxine 75 mg daily were sequentially added with mild benefit on sleep and depressive symptoms, respectively. His cognition continued to deteriorate despite a trial of rivastigmine. Unfortunately, he later suffered multiple strokes, severely affecting his cognition and ambulation, rendering him wheelchair bound. His condition deteriorated further and he died 7 years after the onset of his symptoms.
Brain autopsy showed mild symmetric cerebral atrophy in the frontal and temporal lobes with multiple grossly evident infarcts. The brain weighed 1260 grams. Microscopic evaluation demonstrated moderate to severe neurofibrillary tangles in mesial temporal structures and association areas of the neocortex, Braak stage V and amyloid, Braak, CERAD (ABC) score of B3, associated with frequent neuritic plaques throughout the neocortex, most prominently in the middle frontal, superior and middle temporal gyri, and inferior parietal lobule resulting in C3 scoring on ABC. Along with extensive beta amyloid deposition (A3), these findings were consistent with a high degree of AD neuropathology per the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria [3–7]. No tau immunoreactive glial deposits were identified. There was mild patchy neuronal loss, moderate neurofibrillary tangles, and scattered senile plaques in the substantia nigra with moderate neuronal cell loss and gliosis in the putamen. There was coexistent cerebrovascular disease, with moderate atherosclerosis of major arteries and diffuse arteriolosclerosis. Remote macroscopic infarcts were noted in the left occipital lobe, right middle frontal gyrus, right anterior medial aspect of superior frontal gyrus, and bilateral cerebellar hemispheres.
This 79-year-old man presented with a 6-year history of worsening gait and balance. He initially complained of heaviness in his legs followed by forgetfulness and a tendency to stumble and fall. He also manifested word-finding difficulties and impaired visual navigation. Four years after symptom onset, he developed paranoid ideation and anxiety during a trial of levodopa to address presumed PD. Within months, he became more belligerent, disinhibited, irritable and uncharacteristically offensive. He frequently cried and endorsed depression. Word-finding difficulties were compounded by semantic paraphasias (“garage” instead of “cabinet”). He had trouble locating food on his plate when eating. His gait continued to deteriorate with increased freezing and instability, ultimately leaving him wheelchair dependent. His mother developed dementia of unknown etiology in her late seventies. On exam, he was alert but his verbal output truncated with hesitations, semantic and phonemic paraphasias, echolalia and palilalia. He was unable to follow three-step commands. He exhibited hypomimia, bradykinesia and rigidity, but no tremor (Additional file 2: Video S2). UPDRS motor score was 32.5 on initial evaluation. He demonstrated frontal-localizing signs, including grasp reflex and perseverative behaviors. His brain MRI showed moderate atrophy in the frontal and temporal lobes, with increased periventricular and deep white matter signal abnormality (Fig. 1b, e). Mini-mental status exam score was 28/30 and MoCA 23/30, with deficits in executive function and delayed recall. Visuospatial orientation as per clock drawing and figure copying was normal despite complaints of impaired visual navigation possibly suggesting an attentional deficit. A diagnosis of probable bvFTD was made based on disinhibition, loss of empathy (based on pejorative comments), frontal dysfunction, and MRI findings. The patient died within a year from his only visit from a myocardial infarction. Amyloid-imaging and cerebrospinal fluid biomarkers were not performed.
Gross pathology demonstrated symmetric cortical atrophy in the frontal, anterior, and mesial temporal lobes. Gross brain weight was 1150 g. Microscopy revealed a high degree of AD neuropathologic changes based on NIA-AA guidelines: widespread beta amyloid deposition (A3), neuritic plaques within the neocortex (C3), and neurofibrillary tangles throughout the mesial temporal structures and association areas of the neocortex (Braak stage V and B3) [3–7]. Additionally, alpha-synuclein-positive Lewy bodies were noted in the brainstem (including substantia nigra) and limbic regions, with coexistent mild gliosis in the putamen, suggesting coexistent Lewy body disease (Limbic type, Braak stage IV) [7, 8]. The limited distribution of α-synuclein pathology in cerebral structures suggested that it contributed to the parkinsonian features but was unlikely to have caused the memory and behavioral complaints. No tau-immunoreactive glial deposits or any TDP-43 positive inclusions were identified.
This 78-year-old woman presented with a 9-month history of worsening mood and behavioral changes associated with language difficulties and parkinsonism. Nine months prior to presentation, family members observed she was overly emotional, crying and laughing often without endorsing sadness or happiness. In the following months, the family noticed an asymmetric rest and action tremor in her right hand and gait shuffling, requiring a walker for ambulation 6 months before presentation. Her speech became dysfluent, with echolalia and palilalia. Forgetfulness worsened and she required assistance in all activities of daily living. When going to the bathroom to wash her hands, she would frequently lower her pants and finish urinating in other rooms. On examination, she had a monotone speech with hypophonia, symmetric bradykinesia and rigidity, mild right-hand rest tremor, and impaired postural reflexes (Additional file 3: Video S3). UPDRS III motor score was 47 on initial evaluation. Root, snout, and glabellar reflexes were present. MoCA score was 8/30 with deficits in all domains, except naming. MRI showed mild diffuse generalized atrophy (Fig. 1c, f). Given her behavioral changes with disinhibition and compulsive behaviors, the patient was diagnosed with possible bvFTD associated with parkinsonism. Levodopa was initiated and titrated up to 500 mg four times daily with moderate benefit on her motor symptoms. Multiple medications were tried over the next few years including valproic acid, lamotrigine, aripiprazole, dextromethorphan/quinidine, and oxazepam with only modest benefit for emotional lability. Citalopram provided the sustained improvement in mood. The patient continued to deteriorate and died 10 years after symptom onset.
Autopsy revealed mild to moderate cortical atrophy, more prominent in the frontal lobes. The brain weighed 1030 grams. The histological hallmarks of Alzheimer disease, abundant neuritic plaques (C3) and neurofibrillary tangles (B3), were identified by beta-amyloid and tau immunohistochemistry. Extensive diffuse deposits of beta-amyloid (A3) were also seen in the cerebrum and cerebellum. By NIA-AA criteria, the findings met criteria for “high level” AD neuropathology [3–7]. Rare, scattered tau-positive neurons were identified in the globus pallidus and putamen but insufficient to be classified as FTD-Tau. Minimal focal neuronal cell loss and gliosis is noted in the substantia nigra with occasional neuromelanin-laden macrophages.
These three cases highlight the extent to which behavioral abnormalities may overshadow cognitive impairment in fvAD, the lesser known focal variant of AD, leading to the clinical misdiagnosis of bvFTD. Some studies have suggested that fvAD accounts for approximately 2–3% of AD, [1, 2], although this figure is likely higher because AD pathology can be found in up to 25% of patients with a clinical diagnosis of bvFTD [9, 10]. The appropriate clinical distinction between fvAD and bvFTD has implications for prognosis, treatment, disease progression, and caregiver burden [11–15].
The clinical diagnosis of bvFTD is currently based on the presence of behavioral changes antedating cognitive deficits with a sensitivity of 76–95% and specificity of 82–95% [16, 17]. Typically, the presentation is characterized by changes in personality and behavior, most notably apathy, disinhibition, loss of self-awareness, and loss of empathy [11, 18]. A dysexecutive cognitive impairment emerges later in the course of the disease with difficulties in sustaining attention and set shifting. bvFTD is most often caused by frontotemporal lobar degeneration (FTLD) proteinopathies, namely tauopathies (of which microtubule-associated protein tau (MAPT) gene mutations are the most common genetic causes), TDP-43 proteinopathies (of which chromosome 9 open reading frame 72 (C9orf72) and progranulin (GRN) gene mutations, in order of frequency, are most common), and less frequently, fused in sarcoma (FUS) proteinopathies . In cases of bvFTD-associated parkinsonism, tau is the most common underlying proteinopathy .
Unlike bvFTD, the phenotype in fvAD is less well delineated, with heterogenous clinical descriptions from case reports and case series. Nevertheless, an early amnestic phase, with memory dysfunction preceding changes in behavior may be more common in fvAD . Not only is the behavior-cognition sequence different between fvAD and bvFTD, but the nature of the impairments may differ as well.
In addition, vascular pathology may confound the evaluation of frontal lobe syndromes, including fvAD and bvFTD. Small and large vessel vasculopathy can disrupt frontal lobe networks in a manner suggestive of (and potentially in addition to) fvAD and bvFTD. The clinical heterogeneity of the clinical entities and overlap of comorbitities make ascertaining the correct diagnosis a humbling experience, as demonstrated by all three of our cases carrying a diagnosis of bvFTD during life but reclassified as fvAD on autopsy.
The Yellow brick road
Acknowledging the limitations of classic literature-based metaphors to provide a memorable analogy to what an otherwise complex clinical dilemma, we propose considering the “Yellow Brick Road” from the Wizard of Oz characters to remember the clinical variables to consider when facing the fvAD vs. bvFTD clinical distinction (Fig. 2).
The Scarecrow, who had no brain, allegorizes fvAD. Without a brain the fvAD Scarecrow lost the ability to consolidate new memories and object knowledge (Fig. 2a). Although fvAD Scarecrow can produce a list of words based on letters, suggesting an intact phonemic fluency, the meanings of words is lost and therefore semantic fluency and semantic knowledge are impaired. fvAD Scarecrow is irritable and paranoid, believing the crows are swarming to torment and steal from him. Furthermore, fvAD Scarecrow is shaky and tremulous, movements that on closer inspection represent myoclonus. The fvAD Scarecrow is also sensitive, the slightest whisper or touch can startle him, because of stimulus-sensitive myoclonus.
The Tin Man symbolizes bvFTD (Fig. 2b). bvFTD Tin Man has no heart, so his behaviors and emotions lack empathy. He engages in ritualistic and perseverative behaviors, repetitively venturing to the forest to chop wood and gorge. His rituals included hyperphagia, making him heavier than the fvAD Scarecrow. Furthermore, bvFTD Tin Man is insufficiently lubricated: the rust at the joints slow him to a parkinsonian state.
Chronology of symptoms
Determining the chronology of symptoms is of fundamental importance in the prediction of the underlying pathology of patients with cognitive and behavioral impairments. Patients with bvFTD tend to present with behavioral changes first, which are followed by executive dysfunction and language disturbances (Fig. 3). Conversely, in fvAD memory impairment is the first abnormality in up to 85% of patients (Fig. 4), with the remainder developing memory impairment within 3 years from symptom onset [1, 22, 23]. Our cases highlight the difficulty in determining the sequence of symptoms, and highlight the heterogeneity of and overlap between the fvAD and bvFTD phenotypes. While not apparent in our cases, studies have demonstrated that executive or behavioral dysfunction typically develop after memory deficits in fvAD [1, 22, 23].
Memory and language dysfunction
Memory impairment may be due to disruptions in any of the three stages of memory processing: registration, consolidation, and retrieval. While registration relies upon the integrity of more diffuse attentional and perceptual networks, consolidation hinges on temporal (hippocampal based) networks, and memory retrieval on frontal networks. While bvFTD patients may have mild difficulty with free recall early in the disease, recognition memory is typically intact and thus patients are able to recognize items with cueing, consistent with a retrieval-predominant deficit . Early recall impairment in fvAD is due to the inability to consolidate memories . As memory is not formed, cueing is of no benefit, which was the case in our patients –a missed clue as to the underlying pathology.
Language impairment also shows different patterns in bvFTD and fvAD. In bvFTD, language dysfunction is initially absent, unlike other frontotemporal dementia phenotypes, namely progressive nonfluent aphasia and semantic dementia . In our experience, the “social-emotional” aspects of speech, rather than language itself, may be impaired, with inability to understand the subtleties and context of conversations, hence the analogy to a “heartless” Tin Man. Progressive language deterioration may occur late in bvFTD. The fvAD Scarecrow, “who lacks a brain”, may more often present with word-finding difficulties, anomia, and semantic paraphasias. Fluency may also be helpful in differentiating both disorders. While semantic (category) fluency is usually impaired to a greater degree in fvAD, phonemic (letter) fluency is more affected in bvFTD . Interestingly, the use of profanity during verbal fluency testing has been shown to be more suggestive of bvFTD than AD . We hypothesize that the use of pejoratives seen in case #2 was a filler for word-finding difficulty, with over-utilization of an overlearned phrase, rather than an indicator of disinhibition. Case #3, in which the patient had progressive anomia, was more typical of fvAD in retrospect.
On the other hand, executive dysfunction may not be helpful in distinguishing between underlying degenerative processes. Only one study has shown worse executive function in fvAD compared to bvFTD but such difference may have been confounded by the presence of comorbidities such as cerebrovascular disease, sleep apnea, medication side effects, metabolic dysfunction, and inflammatory conditions . The associated cerebrovascular disease in cases #1 and 2 may have contributed to non-specific frontal dysfunction.
Personality change and behavioral disturbances
Personality changes are more common in patients with bvFTD than fvAD, with differences in the nature of the personality change shedding light on the underlying diagnosis [10, 22]. Patients with bvFTD are most likely to exhibit disinhibition, and are often described as socially inappropriate . Moreover, unlike fvAD “Scarecrows”, bvFTD “Tin Men” may be cold, more apathetic and less empathetic, creating tension with caregivers. We hypothesize the mental rigidity of bvFTD prevents shifting viewpoints and fixate on just one. Relatedly, bvFTD patients may exhibit compulsive perseverative thoughts or behaviors, including collecting, hoarding, and hyperphagia, while these compulsive changes are typically absent in fvAD .
Recognizing behavioral changes may not be obvious, as dementia tends to insidiously exaggerate pre-morbid personality traits. Whereas irritability and depression, as in Case #2, and emotional lability, as in Case #3, may be more common in fvAD, constricted affect and apathy are more typical in bvFTD. The bvFTD “Tin Man” is more emotionally constrained, whereas the fvAD “Scarecrow” is often depressed and may be overburdened by delusions and aggressive behaviors. Each profile creates a distinct caregiver burden in these disorders [22, 27].
One particularly useful clinical scenario to inquire about is meal time. bvFTD patients eating habits may be significantly altered, with hyperphagia and food rituals, and a tendency to seek out and eat one type of food, such as high-carbohydrate meals, with resultant weight gain. This contrasts with the weight loss typical of fvAD patients. Lastly, because of disinhibition and lack of empathy, bvFTD patients have poor table manners, and may engage in eating off tablemates’ plates or uncouthly eating with their hands.
Motor manifestations may yield valuable insights in distinguishing bvFTD from fvAD. As cortical myoclonus is documented in about 50% of patients with fvAD,  its presence favors fvAD over bvFTD. The clinician can imagine, for the purpose of mnemonics, the wind jolting fvAD Scarecrow because of spontaneous and stimulus-sensitive cortical myoclonus of the hands and face in contrast with the poorly lubricated bvFTD Tin Man, which instead renders him parkinsonian.
Parkinsonism is indeed present in 20–30% of patients with bvFTD. When prominent, mutations in the microtubule-associated protein tau (MAPT) tend to be more common than mutations in GRN or C9orf72 genes [29, 30]. A symmetric tremorless parkinsonism with axial rigidity and supranuclear gaze palsy has been shown to be highly predictive of progressive supranuclear palsy pathology due to MAPT or, less commonly, C9orf72 mutations. On the other hand, a corticobasal syndrome (asymmetric parkinsonism with limb dystonia, apraxia, and cortical sensory loss) is more often due to AD pathology than corticobasal degeneration or other disorders . While parkinsonian features may be present in up to 30% of patients with AD,  these appear later in the disease course . The parkinsonian features of Case #2, however, were likely contributed to by Lewy body pathology, which not uncommonly co-occurs with AD. Finally, the coexistence of motor neuron disease strongly suggests pathogenic C9orf72 mutations .
Structural neuroimaging may also provide clues in the assessment of these patients. In fvAD there is greater temporal than frontal atrophy, particularly in the perisylvian area compared to bvFTD [21, 33]. In bvFTD, frontal regions are more affected, particularly the anterior cingulate, orbitofrontal cortex, middle and superior frontal gyrus [21, 33].
Cerebrospinal fluid (CSF) biomarkers studies are invaluable in distinguishing between fvAD from bvFTD and healthy controls [25, 34, 35]. Useful CSF biomarkers include total tau (t-tau), phosphorylated tau (p-tau), and amyloid β-42 (Aβ42). A higher p-tau/Aβ42 ratio (>0.21) is observed in fvAD compared to bvFTD (sensitivity and specificity of about 92%) . In one small series, APOE ε4 carriers were observed in 52% of patients with fvAD compared to 19% with bvFTD and 17% controls . Hence, the presence of APOE ε4 allele makes fvAD more likely than bvFTD.
While no randomized clinical trials have been undertaken in fvAD, acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) have been shown to be effective in classic AD but not in bvFTD . In fact, some bvFTD patients may experience behavioral or cognitive deterioration when exposed to these agents . Likewise memantine, an NMDA receptor antagonist, approved for moderate to severe AD, has shown no benefit in patients with bvFTD . Thus, the different pharmacologic response to treatment in AD versus bvFTD highlights the need to clinically distinguish these disorders. Future clinical trials will require greater sophistication in patient selection not only for symptomatic but also disease-modifying interventions, and will assist efforts in developing reliable serologic and imaging biomarkers of disease trait and progression for each form of frontal dementia.
Our cases highlight several features, which in hindsight should have supported a diagnostic revision to fvAD from bvFTD: early memory involvement, impaired semantic fluency, paraphasic errors and myoclonus (Table 1). Distinguishing between fvAD and bvFTD may be challenging for the clinician, as evidenced by our three cases whom were initially diagnosed with bvFTD but were found to have primarily AD pathology. Improving the clinical diagnosis of bvFTD and fvAD is important to optimize patient care, improve disease-specific counseling to patients and caregivers, and assist with selective patient recruitment for future studies of disease-modifying interventions. While disease-specific biomarkers remain elusive, larger case series may further refine the Wizard of Oz analogy to help in the clinical distinction between fvAD and bvFTD.
Amyloid, Braak, and CERAD rating scale
Behavioral variant of frontotemporal dementia
Chromosome 9 open reading frame 72
Consortium to establish a registry for Alzheimer’s disease
Cerebral spinal fluid
Frontal assessment battery
Frontotemporal lobar degeneration
Frontal variant of Alzheimer’s disease
Microtubule-associated protein tau
Montreal cognitive assessment
National Institute on Aging Alzheimer’s Association
Unified Parkinson’s disease rating scale
Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR. Focal cortical presentations of Alzheimer’s disease. Brain. 2007;130:2636–45.
Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther. 2013;5:1.
Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–8. discussion 278–284.
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–86.
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.
Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.
Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain. 2005;128:1996–2005.
Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952–62.
Neary D, Snowden JS, Mann DM. Classification and description of frontotemporal dementias. Ann N Y Acad Sci. 2000;920:46–51.
Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the cache county dementia progression study. Am J Psychiatry. 2015;172:460–5.
Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev. 2015;3:Cd009444.
Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;25:Cd005593.
Adelman RD, Tmanova LL, Delgado D, Dion S, Lachs MS. Caregiver burden: a clinical review. JAMA. 2014;311:1052–60.
Harris JM, Gall C, Thompson JC, Richardson AM, Neary D, Du Plessis D, Pal P, Mann DM, Snowden JS, Jones M. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology. 2013;80:1881–7.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, Van Swieten JC, Seelaar H, Dopper EG, Onyike CU, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.
Waldo ML. The frontotemporal dementias. Psychiatr Clin North Am. 2015;38:193–209.
Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, De Deyn PP, Santens P, Van Broeckhoven C, Cruts M. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 2012;124:353–72.
Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45:343–9.
Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, Kramer JH, van der Vlies AE, Joie RL, Rosen HJ, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138:2732–49.
Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology. 2013;80:561–8.
Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, Möller C, Lehmann M, van Berckel BN, Seeley WW, Pijnenburg YA, Gorno-Tempini ML, Kramer JH, Barkhof F, Rosen HJ, van der Flier WM, Jagust WJ, Miller BL, Scheltens P, Rabinovici GD. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp. 2015;36(11):4421-37. doi: 10.1002/hbm.22927.
Karantzoulis S, Galvin JE. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother. 2011;11:1579–91.
Bertoux MK Aurélie, Azuar C, Lamari F, Cruz de Souza L, Sarazin M, Samri D, Funkiewiez A, Dubois B, Odile HM. Frontal presentation of Alzheimer’s disease. A series of patients with biological evidence by CSF biomarkers. Dementia & Neuropsychologia. 2013;7(1):66–74.
Ringman JM, Kwon E, Flores DL, Rotko C, Mendez MF, Lu P. The use of profanity during letter fluency tasks in frontotemporal dementia and Alzheimer disease. Cogn Behav Neurol. 2010;23:159–64.
Leger GC, Banks SJ. Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia. Dement Geriatr Cogn Disord. 2014;37:104–12.
Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, Pritchard A, Lendon CL, Richardson AM, Varma A, et al. Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex. 2007;43:835–45.
Wilke C, Pomper JK, Biskup S, Puskas C, Berg D, Synofzik M. Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol. 2016.
Siuda J, Fujioka S, Wszolek ZK. Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat Disord. 2014;20:957–64.
Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, Huang EJ, Trojanowski JQ, Growdon ME, Jang JY, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70:327–40.
Portet F, Scarmeas N, Cosentino S, Helzner EP, Stern Y. Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol. 2009;66:1120–6.
Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, Moller C, Lehmann M, Van Berckel BN, Seeley WW, Pijnenburg YA, Gorno-Tempini ML, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer’s disease. Hum Brain Mapp. 2015;36:4421–37.
De Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82:240–6.
Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, De Koning I, Clark CM, Rosso S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827–35.
Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, Brashear R. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85.
Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84–7.
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–56.
Availability of data and materials
RPS researched the of data and composed the paper. FRP, researched of data, analyzed video files, and provided critical revision for intellectual content. MH provided pathologic evaluation and aided in composition of paper. RS aided in analysis of the cases from a behavioral neurology perspective and provided critical revision for intellectual content. AJE examined and recorded the patients, provided analysis of movement disorders of patients, and engaged in critical revision for intellectual content. All authors read and approved the final manuscript.
RPS has no competing interests
FRP has no competing interests
MH has no competing interests
RS has no competing interests
AJE has received grant support from the NIH, CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay, Abbott, Chelsea Therapeutics, TEVA, Impax, Merz, Lundbeck, and Eli Lilly; honoraria from TEVA, UCB, the American Academy of Neurology, and the Movement Disorders Society; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer.
Consent for publication
Consent for video recording, case reporting, and pathology of cases were obtained using institutional consent forms and processes. These can be made available upon request.
Ethics approval and consent to participate
Not applicable. Autopsy tissue consent provided by patient families under consent for publication.